Clinical applications of the antiprogestins.
Kettel
L M
LM
University of California at San Diego, USA.
D000021:Abortifacient Agents, Steroidal / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D002986:Clinical Trials as Topic; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D003480:Cushing Syndrome / Q000188:drug therapy; D004715:Endometriosis / Q000139:chemically induced; D004717:Endometrium / Q000187:drug effects; D005260:Female; D006727:Hormone Antagonists / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy; D008577:Meningeal Neoplasms / Q000188:drug therapy; D008579:Meningioma / Q000188:drug therapy; D008597:Menstrual Cycle / Q000187:drug effects; D015735:Mifepristone / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D011247:Pregnancy; D011271:Pregnancy, Ectopic / Q000188:drug therapy; D011293:Premenstrual Syndrome / Q000188:drug therapy; D011372:Progestins / Q000037:antagonists & inhibitors*; D014594:Uterine Neoplasms / Q000188:drug therapy
D000021:Abortifacient Agents, Steroidal; D003280:Contraceptives, Oral, Synthetic; D006727:Hormone Antagonists; D011372:Progestins; D015735:Mifepristone